{
    "nctId": "NCT03185169",
    "briefTitle": "GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors",
    "officialTitle": "GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors",
    "overallStatus": "TERMINATED",
    "conditions": "Genitourinary Abnormality, Breast Cancer Female, Vaginal Abnormality, Urinary Tract Infections, Dyspareunia, Dysuria",
    "studyType": "INTERVENTIONAL",
    "phase": "EARLY_PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 14,
    "primaryOutcomeMeasure": "Improvement of GSM signs and/or symptoms",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Female\n2. Postmenopausal women (defined as last menstrual period \\> 1 year ago or 6 months ago with FSH \\>40) who have been diagnosed with breast cancer including in situ carcinoma (DCIS, LCIS)\n3. Have self-identified GSM signs and objective symptoms on baseline screening\n4. Patients already using Replens\u2122 or coconut oil will have a two week washout period prior to starting study treatment.\n5. Medical History review and Pelvic Exam by a board certified gynecologist for baseline assessment OR medical records review by a board certified gynecologist or delegated study staff to confirm diagnosis of GSM. If GSM is to be verified by medical record review, the sub-investigator will make the final determination of eligibility.\n\nExclusion Criteria:\n\n1. Use of any estrogen containing product within 4 weeks prior to screening\n2. Endometrial hyperplasia, endometrial cancer, or other gynecologic malignancy\n3. Patients with non GSM related signs and symptoms as verified by a board certified gynecologist will be excluded.\n4. Any concurrent illness or disorder that, per the opinion of the investigator, would preclude the patient from meeting the study requirements.",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}